Does Novartis make COSENTYX?

Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis | Novartis.

What is the brand name for secukinumab?

COSENTYX® (secukinumab)

What class of drugs is secukinumab?

Secukinumab injection is in a class of medications called monoclonal antibodies. It works by stopping the action of certain cells in the body that cause the symptoms of psoriasis.

What is secukinumab made of?

Each COSENTYX Sensoready pen or prefilled syringe contains 150 mg of secukinumab formulated in: L-histidine/histidine hydrochloride monohydrate (3.103 mg), L-methionine (0.746 mg), polysorbate 80 (0.2 mg), trehalose dihydrate (75.67 mg), and Sterile Water for Injection, USP, at pH of 5.8.

What are the side effects of Cosentyx?

Common side effects of Cosentyx include:

• sore throat and nose,
• diarrhea,
• upper respiratory tract infection,
• sinus infection (sinusisits),
• stuffy or runny nose,
• oral herpes,
• hives,
• athlete’s foot,

How much does Cosentyx cost per month?

If you don’t have prescription drug coverage, the list or wholesale price of COSENTYX as of January 2021 is $5,929.33 a month for either 150-mg or 300-mg dose strength packages, and as of May 2021, $2,964.67 for the 75-mg dose strength package.

Who is the lady in the Cosentyx commercial?

Cyndi Lauper showcases backstage psoriasis woes in Novartis’ new Cosentyx spot.

Who should not take COSENTYX?

COSENTYX is not recommended for children and adolescents (under 18 years of age) because it has not been studied in this age group. COSENTYX may be used by people aged 65 years and over.

What happens if you stop taking COSENTYX?

If you stop using Cosentyx It is not dangerous to stop using Cosentyx. However, if you stop, your psoriasis, psoriatic arthritis or axial spondyloarthritis symptoms may come back. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.

Is Secukinumab safe?

The effect of secukinumab therapy in all these indications has corresponding effects on improvement in quality-of-life and daily activities. Overall, secukinumab is an effective and safe treatment choice for patients suffering from psoriatic disease in its multiple clinical variants.

Does Secukinumab lower immune system?

Official Answer. The biologic drug Cosentyx (secukinumab) can weaken your immune system, increasing your risk of infection. Two of the most common adverse reactions to the drug were colds and upper respiratory tract infections in clinical trials, but this occurred in less than 1% of people.

When was Secukinumab approved for use in adults?

Secukinumab was discovered and developed by Novartis using developmental name AIN457, and the first publication was a Phase I trial published in 2010. In January 2015, secukinumab was approved in the United States and in the European Union to treat adults with moderate-to-severe plaque psoriasis.

What is the molecular formula of secukinumab 125504?

BLA 125504 Jill Merrill 7 CodeName AIN457 Chemical Name Secukinumab Molecular Formula/Molecular Weight C6854H10134N1754O2042S44/ 147.9 kDa Biochemical Description AIN457 is an IgG antibody and consists of Pharmacologic Class Fully human monoclonal antibody that binds and neutralizesIL-17A 2.2 Relevant INDs, BLAs and DMFs

Where is Secukinumab found in the human body?

Secukinumab is a recombinant fully human IgG1/kappa monoclonal antibody and is manufactured in Chinese hamster ovary cells. Secukinumab was discovered and developed by Novartis using developmental name AIN457, and the first publication was a Phase I trial published in 2010.

What does Secukinumab do to the IL-17 receptor?

Secukinumab binds to IL-17A, thereby inhibiting its interaction with the IL-17 receptor. Preventing the cytokine/receptor interaction, neutralizesthe bioactivity of IL-17A and inhibits the subsequent release of proinflammatory cytokines, chemokines, and mediators of tissue damage.